Compare XELB & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XELB | VTGN |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 9.5M |
| IPO Year | 2011 | 2014 |
| Metric | XELB | VTGN |
|---|---|---|
| Price | $0.33 | $0.18 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | ★ $4.00 | $1.00 |
| AVG Volume (30 Days) | 628.8K | ★ 718.4K |
| Earning Date | 11-16-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | $30.13 | $33.96 |
| Revenue Next Year | $99.55 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.27 | $0.17 |
| 52 Week High | $2.47 | $5.14 |
| Indicator | XELB | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.51 | 43.57 |
| Support Level | $0.29 | $0.17 |
| Resistance Level | $0.58 | $0.32 |
| Average True Range (ATR) | 0.09 | 0.01 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 16.79 | 64.29 |
Xcel Brands Inc is a media and brand management company. It is engaged in design, merchandising and planning, sourcing and production, licensing, marketing, and brand development. The company offers branded apparel, footwear, accessories, jewelry, home goods, and other consumer products. Its brand portfolio consists of the Isaac Mizrahi, Judith Ripka, H Halston, C Wonder, and the Highline Collective brands. The company licenses its brands to third parties, provides certain designs, production, and marketing services, and generates licensing, design, and service fee revenues through contractual arrangements and other agreements.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.